Cargando…

Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus

Detalles Bibliográficos
Autores principales:	Jin, Zhili, Wang, Yini, Wang, Jingshi, Zhang, Jia, Wu, Lin, Wang, Zhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647074/ https://www.ncbi.nlm.nih.gov/pubmed/30830248 http://dx.doi.org/10.1007/s00277-019-03647-5

Ejemplares similares

Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study
por: Song, Yue, et al.
Publicado: (2021)

PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis
por: Wang, Jingshi, et al.
Publicado: (2016)

Epstein-Barr virus gastric ulcer associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center
por: Song, Yue, et al.
Publicado: (2020)

Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab
por: Wei, Na, et al.
Publicado: (2021)

Successful Treatment of Relapsed Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis After Allo-HSCT with PD-1 Blockade: A Case Report
por: Pi, Yubo, et al.
Publicado: (2022)

Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib
por: Song, Yue, et al.
Publicado: (2022)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Programmed death 1 monoclonal antibody helped to treat mixed chimeric and reactivation of Epstein-Barr virus in a patient with adult-onset chronic active Epstein-Barr virus infection after allogeneic hematopoietic stem cell transplantation: A case report
por: You, Yahong, et al.
Publicado: (2022)

The Treatment Based on Ruxolitinib and Amphotericin B is Effective for Relapsed Leishmaniasis-Related Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review
por: Cui, Tingting, et al.
Publicado: (2022)

A case of T‐cell‐Epstein–Barr virus‐haemophagocytic lymphohistiocytosis and sustained remission following ruxolitinib therapy
por: Ali, Syed, et al.
Publicado: (2023)

Development of a Nomogram to Predict the Risk of Chronic Active Epstein-Barr Virus Infection Progressing to Hemophagocytic Lymphohistiocytosis
por: He, Xiaodan, et al.
Publicado: (2022)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

Massive pericardial effusion due to chronic active Epstein–Barr virus infection successfully treated with PD-1 blockade: A case report
por: Pi, Yubo, et al.
Publicado: (2022)

Evidence of Epstein–Barr Virus in Female Breast Cancer
por: ALINEZHAD, Farbod, et al.
Publicado: (2021)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma
por: Liu, Weiping, et al.
Publicado: (2023)

Mild form of Guillain-Barré syndrome in a patient with primary Epstein-Barr virus infection
por: Kim, Se Yong, et al.
Publicado: (2016)

Is Epstein–Barr virus associated with aggressive forms of breast cancer?
por: Khan, G, et al.
Publicado: (2011)

Epstein-Barr virus-derived vector suitable for long-term expression in neurons
por: Kiyosue, Kazuyuki, et al.
Publicado: (2020)

The Epstein-Barr Virus
por: Payne, L. N.
Publicado: (1980)

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023)

The Emergence of Epstein-Barr Virus-Related Diffuse Large B-Cell Lymphoma With Mogamulizumab
por: Wang, Lan, et al.
Publicado: (2020)

Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report
por: Huang, Zoufang, et al.
Publicado: (2021)

Reply: Is Epstein–Barr virus associated with aggressive forms of breast cancer?
por: Mazouni, C, et al.
Publicado: (2011)

Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients
por: Yao, Shuyan, et al.
Publicado: (2022)

Long non-coding RNAs in Epstein–Barr virus-related cancer
por: Liu, Yitong, et al.
Publicado: (2021)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Epstein–Barr virus EBNA2 phase separation regulates cancer‐associated alternative RNA splicing patterns
por: Peng, Qiu, et al.
Publicado: (2021)

Impaired Long‐term T Cell Immunity to Epstein‐Barr Virus in Patients with Nasopharyngeal Carcinoma
por: Tamura, Shinji, et al.
Publicado: (1992)

Epstein–Barr virus serology and gastric cancer incidence and survival
por: Koshiol, J, et al.
Publicado: (2007)

Elderly‐onset systemic Epstein–Barr virus‐positive T‐cell lymphoma of childhood
por: Nishikubo, Masashi, et al.
Publicado: (2022)

Epstein - Barr virus Pneumonitis
por: McManus, Terence E, et al.
Publicado: (2009)

Epstein–Barr virus vaccines
por: Cohen, Jeffrey I
Publicado: (2015)

Epstein–barr virus vaccines
por: Cohen, Jeffrey I
Publicado: (2015)

Epstein-Barr virus and skin
por: Sangueza-Acosta, Martin, et al.
Publicado: (2018)

Epstein-Barr Virus Gastritis
por: Oki, Masayuki, et al.
Publicado: (2017)

Resurrecting Epstein–Barr Virus
por: Paganelli, Roberto
Publicado: (2022)

The Epstein Barr virus circRNAome
por: Ungerleider, Nathan, et al.
Publicado: (2018)

Skewed T cell responses to Epstein-Barr virus in long-term asymptomatic kidney transplant recipients
por: Nakid-Cordero, Cecilia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_636tecbngjhujuk4bs2h63b6qa